Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 986-990. doi: 10.19723/j.issn.1671-167X.2018.06.008

• Article • Previous Articles     Next Articles

Clinical characteristic of 74 cases of malignant tumor in rheumatoid arthritis

Yu-hua WANG,Guo-hua ZHANG,Ling-ling ZHANG,Jun-li LUO,Lan GAO,Mian-song ZHAO()   

  1. Department of Rheumatology and Immunology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
  • Received:2018-07-06 Online:2018-12-18 Published:2018-12-18
  • Contact: Mian-song ZHAO E-mail:zmsdoctor@163.com
  • Supported by:
    Supported by Beijing National Science Foundation(7123220);Capital Medical University Research and Cultivation Fund PYZ(PYZ 2017039);Capital Medical University Foundation-Clinical Research Cooperation Fund(13JL64)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the clinical characteristics of rheumatoid arthritis (RA) patients with malignant tumor.Methods:Retrospective summary was made of 1 562 in patients of RA from January 2011 to June 2017.In the study, 74 RA patients with malignant tumor were reviewed and analyzed, and the general conditions, tumor types, RA and tumor onset sequence, and the medication situation were analyzed.Results:The incidence of malignant tumor in the patients with rheumatoid arthritis in our center was 4.16 %. The 74 patients were complicated with malignant tumor, of whom 53 were female,and 21 male. The age of RA at presentation was (52.6±17.8) years. The average disease duration of malignant tumor was (63.4 ± 12.7) years. The onset time of rheumatoid arthritis was earlier than that of malignant tumors in 51 cases (51/74), with an average of (17.2±14.2) years between 2 and 60 years. The incidence of malignant tumor was earlier than that of rheumatoid arthritis in 16 cases (16/74), with an average of (6.2±5.9) years between 1 and 21 years, of which 10 cases were sex hormone related tumors. Seven cases (7/74) were diagnosed with RA at the same time, and the time interval between the two diseases was within 1 year. All the patients were over 60 years old with digestive tract tumors. All the 7 patients showed polyarthritis, significantly increased erythrocyte sedimentation rate and C-reactive protein, including 4 rheumatoid factor positive cases and 2 anti-CCP antibody positive cases. The effect of non-steroidal anti-inflammatory drugs and traditional drugs to improve the condition of the disease was poor in the 7 patients, and the condition was relieved after using low-dose glucocorticoids. Gastrointestinal tumors, breast and reproductive system tumors were the most common, followed by respiratory, urological and blood system tumors.Conclusion:The risk in patients of rheumatoid arthritis complicated with malignant tumor is higher than that of the general population. A variety of factors play an important role in cancer risk of RA, including disease activity, some estrogen metabolites, the use of drugs and so on. Therefore, all RA patients should be screened for malignant tumor during diagnosis, and malignant tumor surveillance is mandatory for all rheumatoid arthritis patients after diagnosis.

Key words: Rheumatoid arthritis, Malignant tumor, Malignant tumor surveillance

CLC Number: 

  • R593.22

Table 1

Main clinical features of RA combined with malignant tumor"

Tumor site Case Tumor diagnosis age/years, x-±s RA diagnosis age/years, x-±s Smoking history, n Tumor onset before/
concurring with/after RA onset
Breast 17 61.6±12.8 59.6±10.4 0 8/0/9
Colorectal 10 64.3±12.7 58.8±19.6 5 4/0/6
Lung 9 73.3±10.1 52.0±21.9 3 0/0/9
Esophagus 5 63.2±7.3 45.2±9.4 1 0/1/4
Lymphoma 5 65.8±14.1 53.6±24.9 0 1/0/4
Prostate 4 73.3±3.4 69.5±7.5 2 1/1/2
Endometrium 3 38.3±27.0 53.3±12.7 0 1/0/2
Pancreas 3 69.3±5.5 62.7±7.1 1 0/2/1
Thyroid 3 44.7±1.5 26.7±3.8 0 0/0/3
Stomach 2 69.0±14.1 47.5±16.3 0 0/1/1
Liver 2 76.0±8.5 57.5±21.9 1 0/0/2
Ovary 2 49.0±12.7 22.0±14.1 0 0/0/2
Biliary duct 1 64 63 0 0/1/0
Cholecyst 1 59 59 0 0/1/0
Periampullar 1 57 32 0 0/0/1
Meninges 1 57 47 0 0/0/1
Glioblastoma 1 61 44 0 0/0/1
Cervical 1 50 37 0 0/0/1
Peritoneal 1 74 55 0 0/0/1
Kidney 1 59 53 0 0/0/1
Testis 1 31 41 1 1/0/0

Table 2

RA and tumor occurrence time"

General information RA onset before tumor RA and tumor occured simultaneously RA onset after tumor
Number of cases 51 7 16
Male :female 14 :37 3 :4 4 :12
Time interval/years 17.2±14.2 0.5±0.3 6.2±5.9
Tumor types and case number Breast/lung 9, colorectal 6,
esophagus/lymphoma 4, thyroid 3, prostate/endometrium/liver/ovary 2, pancreas/stomach/periampul-
lar/meninges/glioblastoma/cer-vical/peritoneal 1		 Pancreas 2, esophagus/prostate/
stomach/biliary duct/cholecyst 1		 Breast 8, colorectal 4, lymphoma/
prostate/endometrium/testis 1
[1] Simon TA, Thompson A, Gandhi KK , et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis[J]. Arthritis Res Ther, 2015,17:212.
doi: 10.1186/s13075-015-0728-9 pmid: 18433475
[2] Turesson C, Matteson EL . Malignancy as a comorbidity in rheumatic diseases[J]. Rheumatology (Oxford), 2013,52(1):5-14.
doi: 10.1093/rheumatology/kes189 pmid: 22829694
[3] Gridley G , McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis[J]. J Natl Cancer Inst, 1993,85(4):307-311.
doi: 10.1093/jnci/85.4.307 pmid: 8426374
[4] Askling J, Fored CM, Brandt L , et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists[J]. Ann Rheum Dis, 2005,64(10):1421-1426.
doi: 10.1136/ard.2004.033993 pmid: 1005157
[5] Smitten AL, Simon TA, Hochberg MC , et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis[J]. Arthritis Res Ther, 2008,10(2):R45.
doi: 10.1186/ar2404 pmid: 18433475
[6] Parikh-Patel A, White RH, Allen M , et al. Risk of cancer among rheumatoid arthritis patients in California[J]. Cancer Causes Control, 2009,20(6):1001-1010.
doi: 10.1007/s10552-009-9298-y pmid: 19184473
[7] Raheel S, Crowson CS, Wright K , et al. Risk of Malignant neoplasm in patients with incident rheumatoid arthritis 1980 -2007 in relation to a comparator cohort: a population-based study [J/OL]. Int J Rheumatol, https: //www.hindawi.com/journals/ijr/2016/4609486/.
[8] Chen W, Zheng R, Baade PD , et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
doi: 10.3322/caac.21338 pmid: 26808342
[9] Ometto F, Fedeli U, Schievano E , et al. Cause-specific mortality in a large population-based cohort of patients with rheumatoid arthritis in Italy[J]. Clin Exp Rheumatol, 2018,36(4):636-642
pmid: 29533757
[10] Pedersen JK, Holst R, Primdahl J , et al. Mortality and its predictors in patients with rheumatoid arthritis: a Danish population-based inception cohort study[J]. Scand J Rheumatol, 2018,47(5):371-377.
doi: 10.1080/03009742.2017.1420223 pmid: 29741136
[11] Manger B, Schett G . Rheumatic paraneoplastic syndromes: a clin-ical link between malignancy and autoimmunity[J]. Clin Immunol, 2018,186:67-70.
doi: 10.1016/j.clim.2017.07.021 pmid: 28736272
[12] Wen J, Ouyang H, Yang R , et al. Malignancy dominated with rheumatic manifestations: a retrospective single-center analysis[J]. Sci Rep, 2018,8(1):1786.
doi: 10.1038/s41598-018-20167-w pmid: 5789019
[13] Wilton KM, Matteson EL . Malignancy incidence, management and prevention in patients with rheumatoid arthritis[J]. Rheumatol Ther, 2017,4(2):333-347.
doi: 10.1007/s40744-017-0064-4 pmid: 28508282
[14] Chiu YM, Lang HC, Lin HY , et al. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan[J]. Int J Rheum Dis, 2014,17(3):9-19.
doi: 10.1111/1756-185X.12539 pmid: 25496045
[15] Harigai M, Nanki T, Koike R , et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan[J]. Mod Rheumatol, 2016,26(5):642-650.
doi: 10.3109/14397595.2016.1141740 pmid: 26873430
[16] Mercer LK, Askling J, Raaschou P , et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers[J]. Ann Rheum Dis, 2017,76(2):386-391.
doi: 10.1136/annrheumdis-2016-209285 pmid: 5284347
[17] Wadstr?m H, Frisell T, Askling J , et al. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice a nationwide cohort study from Sweden[J]. JAMA Intern Med, 2017,177(11):1605-1612.
doi: 10.1001/jamainternmed.2017.4332 pmid: 28975211
[18] Mercer LK, Galloway JB, Lunt M , et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis[J]. Ann Rheum Dis, 2017,76(3):497-503.
doi: 10.1136/annrheumdis-2016-209389 pmid: 24685910
[19] de La Forest Divonne M, Gottenberg JE, Salliot C . Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers[J]. Joint Bone Spine, 2017,84(2):133-140.
doi: 10.1016/j.jbspin.2016.02.028 pmid: 27341745
[20] Khan WA, Khan MW . Cancer morbidity in rheumatoid arthritis: role of estrogen metabolites [J/OL]. Biomed Res Int, https: //www.ncbi.nlm.nih.gov/pmc/articles/PMC3789363/.
[21] Joseph RM, Movahedi M, Dixon WG , et al. Smoking-related mortality in patients with early rheumatoid arthritis: a retrospective cohort study using the clinical practice research datalink[J]. Arthritis Care Res (Hoboken), 2016,68(11):1598-1606.
doi: 10.1002/acr.22882 pmid: 26990778
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[3] Yan DING, Lifang WANG, Chaoran LI, Zhemin LU, Lianjie SHI. Rheumatoid arthritis combined with IgG4-related disease successfully treated with rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1203-1207.
[4] Ju YANG, Jing XU, Juhua DAI, Lianjie SHI. Expression of lumican protein in serum of patients with rheumatoid arthritis and its correlation with disease and immune activities [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 911-918.
[5] Lianghua FENG, Lirong HONG, Yujia CHEN, Xueming CAI. Role and mechanism of ubiquitin-specific protease 35 in ferroptosis of rheumatoid arthritis-fibroblast like synoviocytes [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 919-925.
[6] Peiwen JIA, Ying YANG, Yaowei ZOU, Zhiming OUYANG, Jianzi LIN, Jianda MA, Kuimin YANG, Lie DAI. Clinical characteristics of overlapping syndromes of low muscle mass in patients with rheumatoid arthritis and their impact on physical function [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1009-1016.
[7] Doudou MA, Zhemin LU, Qian GUO, Sha ZHU, Jin GU, Yan DING, Lianjie SHI. Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1110-1114.
[8] Rui YAN, Dan KE, Yan ZHANG, Li LI, Huanran SU, Wei CHEN, Mingxia SUN, Xiaomin LIU, Liang LUO. Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 956-962.
[9] Liang ZHAO, Chenglong SHI, Ke MA, Jing ZHAO, Xiao WANG, Xiaoyan XING, Wanxing MO, Yirui LIAN, Chao GAO, Yuhui LI. Immunological characteristics of patients with anti-synthetase syndrome overlap with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 972-979.
[10] Yijun HAN, Xiaoli CHEN, Changhong LI, Jinxia ZHAO. Application status of methotrexate in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 994-1000.
[11] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[12] Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[13] Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[14] Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[15] Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd